Introduction
============

Mucopolysaccharidosis IVA (MPS IVA, Morquio syndrome type A) is a genetic disease with an autosomal recessive inheritance that has been classified as a rare disease. The absence of or partial deficiency of the enzyme N-acetyl-galactosamine-6-sulfate sulfatase (GalNAc-6-sulfatase, GALNS, E.C.3.1.6.4), responsible for degradation of glycosaminoglycans keratan sulfate and chondroitin 6-sulfate, leads to the pathological accumulation of these compounds in the body tissues, specifically at bone, cartilage, heart, and lungs.[@b1-tacg-11-045]

The disease prevalence for the general population has been estimated in 1:201,000 live births.[@b2-tacg-11-045] Frequency in Colombian population was presented by Gómez et al: the overall frequency of all types of MPS was 1.98 per 100,000 live births, MPS type IV being the highest one, with a frequency of 0.68 per 100,000 live births.[@b3-tacg-11-045]

There is also evidence that confirms the disease's existence in local ancient cultures. Bernal and Briceño performed an examination of pottery collections from Tumaco-La Tolita culture (from the middle of the first millennium BC until the third century AD) and described human figures with features that suggest the presence of MPS type I and IV, along with other inheritable diseases.[@b4-tacg-11-045]

Studies in MPS IVA have been carried out in Colombian population, such as that performed in 1996 by Kato et al. Three missense mutations were identified in a sample of 12 patients; these pathogenic variants were p.Gly301Cys, p.Ser162Phe, and p.Phe69Val.[@b5-tacg-11-045]

As MPS type IV is the most frequent MPS in Colombia, performing an updated study regarding the clinical and mutational characteristics of the patients will help to establish a new reference in MPS IVA in the country.

Materials and methods
=====================

The Ethics Committee of the National University of Colombia approved the study, and 32 patients from different regions of the country were included. According to local regulations, the parents or legal guardians of the minors provided their informed consent for participation before being enrolled (assent of the minors was also obtained). The main inclusion criterion referred to patients diagnosed with MPS IVA via clinical, biochemical and genetic/radiological evaluation to measure the activity of the enzyme N-acetyl-galactosamine-6-sulfate sulfatase in leukocytes. Data was analyzed based on the Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA published in 2013.[@b6-tacg-11-045]

Exploratory data analysis was performed by using percentages and frequency tables for discrete and categorical variables; continuous variables were analyzed using central tendency and dispersion measures. SPSS (free trial version 21.0) was the statistical software used.

Genomic DNA was extracted by using the Ultraclean® Blood DNA Isolation Kit. Amplification of the 14 exons including the intron-exon boundaries of the *GALNS* gene was carried out with the primers designed employing the online software Primer 3, as reported by Pajares et al[@b7-tacg-11-045] and synthesized by Invitrogen ([Table S1](#SD2-tacg-11-045){ref-type="supplementary-material"}). Therefore, PCR amplification was done in MyCycler and T100 Bio-Rad® thermocyclers. Sequencing was completed by using an ABI PRISM 3500 automated sequencer (Applied Biosystems).

For reporting gene variants, retrieved electropherograms were analyzed with program BioEdit v7.2.5 Sequence Alignment Editor (<http://www.mbio.ncsu.edu/BioEdit/page2.html>; Tom Hall Ibis Therapeutics (a division of Isis Pharmaceuticals), Carlsbad, CA, USA) and compared to the GALNS reference sequence NG_008667. The new variants were classified and analyzed by using the SIFT platforms (<http://sift.jcvi.org/www/SIFT_enst_submit.html>; Craig Venter Institute, CA, USA), PolyPhen 2 (<http://genetics.bwh.harvard.edu/pph2/>; Biobyte Solutions, Heidelberg, Germany), Mutation Taster (<http://www.mutationtaster.org>; NCBI 37/Ensembl 69, Schwarz, Cooper, Schuelke, Seelow), PMUT (<http://mmb2.pcb.ub.es/PMut/>; IRB Barcelona Institute for Research in Biomedicine), PhD-SNP (<http://snps.biofold.org/phd-snp/phd-snp.html>), and FATHMM (<http://fathmm.biocompute.org.uk>; University of Bristol Integrative Epidemiology Unit, UK) and taking into account the ACMG recommendations for evaluating the variants.[@b8-tacg-11-045]

Molecular docking was carried out for wild-type GALNS and mutants. As described by Rivera-Colón et al,[@b9-tacg-11-045] homology modeling was performed using the structure of the protein N-acetyl-galactosamine-6-sulfate-sulfatase. Two structures were utilized for this analysis with accession numbers 4FDI and 4FDJ from the Protein Data Bank (PDB) (<https://www.rcsb.org/pdb/home/home.do>; Collaborative Research for Structural Bioinformatics: Rutgers and UCSD/SDSC). Modeling was accomplished with a template of wild-type structure of GALNS code 4FDI (due to its 2.2 Å resolution) using the SWISS-model platform. The X, Y, and Z coordinates to be used in AutoDock Tools (version 1.5.6) were calculated with the eFindsite platform (<http://brylinski.cct.lsu.edu/efindsite>; Louisiana State University). Calculations led to seven options for pocket coordinates, and the authors selected the one with the best confidence interval. Option 1 was chosen for G6S substrate (confidence interval: 0.9580).[@b10-tacg-11-045] Molecular docking between the enzyme and the ligand was performed in silico; affinity energy (kcal/mol) values were obtained by using AutoDock Vina 1.0[@b11-tacg-11-045] (<http://autodock.scripps.edu/news/autodock-vina-1-0-released>; The Scripps Research Institute) and AutoDock Tools (Version 1.5.6) (<http://mgltools.scripps.edu/downloads>; The Scripps Research Institute).

For estimating the energy values for wild-type GALNS bindings and the mutants models, N-acetylgalactosamine-6-sulfate (GalNAc6S; PubChem CID:193456) was used as the ligand molecular docking results were visualized with LigPlot+ (<http://www.ebi.ac.uk/thornton-srv/software/Lig-Plus/>; EMBL-EBI, Wellcome Genome Campus, Hinxton, Cambridgeshire, UK).[@b12-tacg-11-045]

Results
=======

Clinical description
--------------------

Thirty-two patients from 30 families were included in the study. Families came from different geographical regions: Andean region, which includes the Cundiboyacense Savannah; the Coffee Triangle region; Antioquia and Tolima departments; and Orinoquia, Pacific, and Caribbean regions. [Table 1](#t1-tacg-11-045){ref-type="table"} shows the demographics and characteristics of patients at study entry.

Parents' consanguinity was reported in 22% of patients (first- and third-degree cousins, uncle--niece relation). As a remarkable matter, both or at least one parents' geographical ancestries were located in the Cundiboyacense Savannah and Coffee Triangle region (32 patients).

At the time of study initiation, 31.3% (10 patients) were attending weekly enzyme replacement therapy.

Frequency of mutations
----------------------

Eleven variants were found in this group of patients. Pathogenic variant c.901G\> T or p.Gly301Cys was the most frequent with 51.6% of the alleles, followed by mutation c.1156C\> T or p.Arg386Cys with 16.1%, and c.485C\> T or p.Ser162Phe with 12.9% of the alleles. A single nonsense mutation in the heterozygous state, corresponding to genotype c.974 G\> A or p.Trp325X, was also detected, as well as a single heterozygous deletion mutation corresponding to genotype c.853_855delTTC or p.Phe285del was also found ([Table 2](#t2-tacg-11-045){ref-type="table"}). It was possible to describe the presence of one new pathogenic variant (not previously reported in the literature) in a heterozygous state, corresponding to genotype c.319 G\> T or p.Ala107Ser ([Table 3](#t3-tacg-11-045){ref-type="table"}).

Of these patients, 56.3% were homozygous: (12) p.Gly301Cys, (3) p.Arg386Cys, (1) p.Ser162Phe, (1) p.Asn164Thr, and (1) p.Ser80Leu, while 43.7% exhibited some combination of compound heterozygosity. Two patients (6.3%) belonging to the same family did not express the mutation in the second allele. Other mutations were also reported for the first time in Colombian population: p.Asn164Thr (4.8%); p.Ser80Leu and p.Ser287Leu (3.2%); p.Arg94Cys, p. Ala107Ser, p.His142Leu, and p.Phe 285del (1.6%); and p.Trp325X (1.6%) ([Figure 1](#f1-tacg-11-045){ref-type="fig"}).

Bioinformatic analysis
----------------------

### Molecular docking of wild-type GALNS

The active site of GALNS is located in domain 1, and the residues of the active site are p.Asp39, p.Asp40, p.Arg83, p.Tyr108, p.Lys140, p.His142, p.His236, p.Asp288, p.Asn289, p.Lys310, and DHA79.[@b9-tacg-11-045]

Wild-type GALNS was docked against its molecular substrate N-acetylgalactosamine-6-sulfate (G6S), with an affinity energy of −5.9 kcal/mol. LigPlot+ visualization of docking results identified intermolecular interactions. The O~2~-sulfate group of N-acetylgalactosamine-6-sulfate interacted with p.Gln111 of GALNS, establishing a hydrogen bond and an electrostatic interaction with p.Tyr108 ([Figure 2](#f2-tacg-11-045){ref-type="fig"} and [Figure S1](#SD1-tacg-11-045){ref-type="supplementary-material"}).

Root mean square deviation (RMSD) and solvent accessible surface area (ASA)
---------------------------------------------------------------------------

Each mutant was modeled by homology with SWISS-model using a 4FDI wild-type GALNS template from the RCSB-PDB database, and then the models were refined at PyMOL. [Table 4](#t4-tacg-11-045){ref-type="table"} summarizes the RMSD and ASA measures for each of the models.

RMSD was calculated by overlapping all mutant GALNS models with 4FDI wild-type GALNS template. Values of RMSD were obtained from the distances calculated between the atoms from both structures expressed in Angstrom (proteins with high similarity in the structure are close to 1 Å). The variants p.Ser80Leu, p.Arg94Cys, p.Ala107Ser, p.His142Leu, p.Ser162Phe, p.Ser287Leu, p.Gly301Cys, and p.Arg386Cys showed structural alterations with RMSD values below 0.5 Å. As the RMSD value was above 1.0 Å, the deletion and nonsense mutations p.Phe285del and p.Trp325X revealed a change affecting the GALNS structure ([Table 4](#t4-tacg-11-045){ref-type="table"}).

ASA was calculated by adding a solvent probe radius of 1.4 Å to the wild-type GALNS, and to the mutant proteins. The ASA result for the wild-type GALNS 18.320 × 10^3^ Å^2^ was used as a reference for mutants' comparison. Mutant proteins exhibiting fluctuations at solvent exposure (ASA value decreased) were p.Ser80Leu, p.Ser162Phe, p.Ser287Leu, and p.Gly301Cys. The p.Trp325X mutant showed a substantial decrease in ASA value of 12.773 × 10^3^ Å^2^ ([Table 4](#t4-tacg-11-045){ref-type="table"}).

Discussion
==========

This study evaluated a sample of the Colombian population with clinical, biochemical, and molecular confirmation of MPS IVA, a size sample larger than that assessed by Kato et al in 1997 (10 Colombian families).[@b5-tacg-11-045] To this date, this is the study with the largest number of genotyped patients reported in Latin America. Thus, it can provide compelling information on the clinical and molecular conditions of MPS IVA in this region.

This clinical and molecular analysis allowed to retrieve and compare data, with extensive available data.[@b13-tacg-11-045],[@b14-tacg-11-045] From a clinical perspective, patients showed similar data regarding the age of inclusion when compared to the global registry of MPS IVA, 15.8 years vs. 14.9 years for male patients and 13.3 years vs. 19.1 years for female patients. Also, the age of symptom onset showed similarity with 2.18 years in this study vs. 2.1 years in the global registry, and symptoms like short stature, skeletal abnormalities, and gait disorder were also similar.

Compared to the Morquio A International Registry,[@b13-tacg-11-045] there were differences regarding phenotype, with a greater number of severely compromised patients, 96.88% vs. 68.4%, that had been reported worldwide. These differences may be explained by underdiagnosis in the attenuated cases, a likelihood to find severe phenotypes in almost all MPS patients of this country.[@b15-tacg-11-045],[@b16-tacg-11-045] and also because of our small sample size (32 patients).

When analyzing medical registries, it was observed that patients had fewer interventions compared to data in the registry: cervical fixation 18.8% vs. 51%, myringocentesis 11.1% vs. 33%, and osteotomies 12.5% vs. 26%. This may reflect that medical staff do not have appropriate knowledge of management guidelines for this pathology.[@b13-tacg-11-045]

Mutational profile
------------------

From a genotypic approach, results were similar to those documented by Morrone et al in 2014.[@b14-tacg-11-045] In this study 56.3% of patients were homozygous, 43.7% had some combination of compound heterozygosity, and only 6.3% showed an alteration in one allele, due to the amplification of only involved exon regions and intron-exon boundaries. Morrone et al reported 257 patients (48%) as homozygous, 212 (39%) as compound heterozygous, and 72 (13%) with an alteration in only one identified GALNS allele.[@b14-tacg-11-045]

Regarding missense mutations, prevalence was higher in this study than that reported in the literature, 93.8% vs. 67%. For nonsense mutations, values showed here are lower than those internationally reported, 3.12% vs. 8%, and for deletions 3.12% vs. insertions and deletions 17%. The authors consider that these findings may be attributed to sample size, which was lower in this study compared to international studies, and also to consanguinity among the population (22% in our sample).

Pathogenic variant p.Gly301Cys showed the highest number of alleles (51.6% in 32 patients), and it was found in all cases in severe forms. Kato et al had reported this mutation in 1997 with a prevalence of 68.4% (12 patients) in the first molecular study conducted with Colombian patients.[@b5-tacg-11-045] This finding confirms the founding effect of this mutation in Colombia.

p.Arg386Cys was the second most frequent pathogenic variant with 16.1%. This has been reported as the most prevalent in the Iberian population[@b7-tacg-11-045] and therefore easily traceable for Colombia.[@b17-tacg-11-045] The third one was p.Ser162Phe (12.9%) with a frequency similar to that reported by Kato et al.[@b5-tacg-11-045]

The p.Asn164Thr variant with uncertain significance was found in a patient with attenuated phenotype in the compound heterozygous state (p.Ser287Leu), and also found in another patient with a severe phenotype that showed a homozygous state. This mutation has been reported in the literature for indeterminate phenotypes.[@b13-tacg-11-045],[@b17-tacg-11-045],[@b18-tacg-11-045] It generates a change in the protein with an interruption in the surface avoiding the proper formation of hydrogen bonds, specifically in the domain 1.[@b9-tacg-11-045] Authors of this study suggest considering this variant with uncertain significance, since it is present in patients with both severe and attenuated phenotypes.

A variant that affects the active site of GALNS c.425A\> T p.His142Leu was a missense type reported by Caciotti et al,[@b19-tacg-11-045] which was found in the patient identified as MPS IVA 029 who exhibited heterozygous state and severe phenotype. This was classified by the authors as deleterious according to the analyses provided by the same prediction software. Notably, p.His142Leu generates a change in the protein, specifically in the domain 1 in the active site. Therefore, it could also be considered as a severe mutation.

One mutation not previously reported was found in heterozygous status in one MPS IVA patient (previous review in databases such as ExAC \[<http://exac.broadinstitute.org/>\], 1000 genomes \[<http://www.internationalgenome.org/>\], NCBI \[<http://www.hgmd.org>, <http://galns.mutdb.org/Database>\]).[@b20-tacg-11-045] Patient identified as MPS IVA 022, with a severe phenotype, exhibited the missense mutation c.319G\>T p.Ala107Ser, considered by the authors as deleterious according to the analyses provided by PolyPhen 2, FATHMM, and Mutation Taster. This was also found to be neutral using bioinformatic tools such as SIFT software, PMUT, and PhD-SNP. This change affects specifically domain 1 on the protein surface, leaving no space for the side chain. Thus, this could be considered as a probably pathogenic variant, considering the results yielded by the bioinformatics tools mentioned above and the severe phenotype found in the MPS IVA 022 patient included in this study.

Bioinformatic analysis
----------------------

RMSD let to confirm that the mutant proteins showed a structural alteration, which generates a substantial distance to the wild-type GALNS. However, it was not possible to compare severe and attenuated forms because it was not possible to find an attenuated mutant and only one patient showed the attenuated phenotype.

This study is the first one showing results of bioinformatic analysis of wild-type GALNS and mutant proteins that used the wild-type GALNS structure obtained by X-ray crystallography and deposited in the PDB. For this reason, it is dif ficult to correlate this data with previous studies performed by Sudhakar and Mahalingam and Olarte et al who analyzed RMSD, ASA, and molecular docking with the G6S ligand, since they used as template a GALNS obtained by homology from another kind of sulfatases.[@b21-tacg-11-045],[@b22-tacg-11-045]

Despite difficulties comparing data presented by Sudhakar and Mahalingam, the authors compared docking results between acetylgalactosamine-6-sulfate ligand and wild-type GALNS and found that the model proposed in this study showed an affinity energy level lower than that obtained for wild-type GALNS, findings similar to those presented by Sudhakar and Mahalingam.[@b21-tacg-11-045]

The most relevant intermolecular interactions between wild GALNS and G6S occurred with three hydrogen bonds: one between the O2-sulfate group of G6S with p.Gln111 and the other two between O9 and O7-sulfate of G6S with p.Tyr170; two more electrostatic interactions were present between p.Tyr108 and p.Cys165. Due to these interactions, there were changes in the docking for the p.Gly301Cys mutant, with an affinity energy level of −5.1 kcal mol, which showed only one electrostatic interaction with p.Trp520. Changes were also found for p.Ser287Leu, with an affinity energy level of −5.1 kcal/mol and showing hydrogen bonds with p.Gln311 and p.Asn106 residues. Regarding the undetermined mutant p.Asn164Thr, it showed an affinity energy level of −5.2 kcal/mol, two hydrogen bonds for p.Gln311 and p.Asn106, and two electrostatic interactions with p.Leu78 and p.Ser521. A variant that affects the active site of GALNS p.His142Leu (classified as severe), with affinity energy levels of −5.1 kcal/mol, presented hydrogen bonds interactions with p.Gln311 and p.Asn106 residues, which differs from the wild-type GALNS.

The molecular docking for the new mutant p.Ala107Ser (classified as severe), with affinity energy levels of −5.2 kcal/mol, showed similar behavior when compared to the other mutants classified as severe, since interactions occurred differed from the wild-type GALNS. The p.Ala107Ser exhibited a hydrogen bond interaction with p.Asn106 and an electrostatic interaction with p.Ser521.

Genotype--phenotype correlation
-------------------------------

In this study, 96.88% of patients presented with severe phenotypes, two patients showed enzymatic activity above 3.5 nmol/mg prot/h, and one patient (3.12%) with attenuated phenotype exhibited enzymatic activity of 0.0 nmol/mg prot/hr. Severe or attenuated denomination used for phenotypes was based on physical features like height, age, and sex as described by Montaño et al.[@b23-tacg-11-045] These authors concluded that it is challenging to confirm correlations between clinical and mutational status in MPS IVA.

Study authors consider that these correlations should be strengthened from other approaches, for example, researchers should go beyond anthropometric characteristics and take into account clinical classification with other parameters such as respiratory compromise, mobility in large and small joints, or even visceral compromise. Bioinformatic analysis may also add RMSD values; even interactions of the molecular docking with the particular substrate can contribute to the discussion. This study did not attempt to establish these correlations; however, it provides some clinical and structural data found in the patients exhibiting different mutations in GALNS.

Conclusion
==========

This study presents a global clinical, molecular, and bioinformatic analysis in a group of Colombian patients with MPS IVA. Clinical variables and genotypic analysis were similar to those reported in the global registry for this disease. Genotypic data presented here showed greater allelic heterogeneity than that previously reported by Kato et al in this population,[@b5-tacg-11-045] Eleven variants were identified, including a new variant in a heterozygous state, corresponding to genotype c. 319 G\>T or p.Ala107Ser.

Regarding the bioinformatic analysis of mutant proteins versus wild-type GALNS, this study showed changes in the three-dimensional structure and the molecular docking results, with a decrease in affinity energy levels in kcal/mol and intermolecular interactions for each substratum.

Although genotype--phenotype correlations are very hard to establish in patients with MPS IVA, it is necessary to continue the discussion about these topics and perform regular reviews of clinical and molecular classifications.

Supplementary materials
=======================

###### 

Docking results of G6S ligand and GALNS interactions using LigPlot+. Hydrogen bonds are represented by green dotted lines and distances between atoms are expressed in Angstroms. Residues involved in hydrophobic interactions are identified (surrounded by a red semicircle). (**A**) Intermolecular interaction of GALNS model with G6S, affinity energy of −5.9 kcal/mol; (**B**) intermolecular interaction of p.Asn164Thr model (indeterminate form) with G6S, affinity energy of −5.2 kcal/mol; (**C**) intermolecular interaction of p.His142Leu model, variant involving a catalytic site residue (severe form) with G6S, affinity energy of −5.1 kcal/mol; (**D**) intermolecular interaction of p.Ala107Ser model, new variant (severe form) with G6S, affinity energy of −5.2 kcal/mol.

###### 

Primers used in PCR

  Primer            Sequence (5′--3′)        Fragment size (bp)   \% G/C
  ----------------- ------------------------ -------------------- --------
  EXON1 GALNS-F     GTACGCACCTCCTTGGCAATCA   441                  54.5
  EXON1 GALNS-R     CACTCACGTCGTCCATGAGC                          60
  EXON2 GALNS-F     ACACGCTCTTGGCACCAT       340                  56
  EXON2 GALNS-R     CCACCCTCCCTGCAGTAGTA                          60
  EXON3 GALNS-F     CGTCTGTCACGCGTCTGT       294                  61
  EXON3 GALNS-R     ACCAGCGGTACCCCACCT                            67
  EXON4 GALNS-F     CCTGGAAAAATCTTGGGAAGT    386                  43
  EXON4 GALNS-R     GACACCCTCCTCATTTGGAA                          50
  EXON5 GALNS-F     CTGGAGGGTGCTCGTCTTAC     347                  60
  EXON5 GALNS-R     ACTTGAGCCCACCAGTGCTA                          55
  EXON6-7 GALNS-F   AAGCCCATGGCTTTGCTG       698                  56
  EXON6-7 GALNS-R   CCATCTCTGGAGTCAAGCAC                          55
  EXON8 GALNS-F     CTGCCTGATCCATTTGTCAC     317                  50
  EXON8 GALNS-R     AGAGGGACCCTTCATGCTCT                          55
  EXON9 GALNS-F     CCCTTTGTCCCTATGACCAG     327                  55
  EXON9 GALNS-R     AGGAGAGCGGTGAGGATGAG                          60
  EXON10 GALNS -F   GTGGGCGTGTGAGCATGTAT     381                  55
  EXON10 GALNS-R    CCTGTGTCCAGAACCAGGAG                          60
  EXON11 GALNS-F    CTTGCGGGCCTTTTTACTTT     371                  45
  EXON11 GALNS-R    GAGTTCCTGCCTGTCTCACC                          60
  EXON12 GALNS-F    CTGCTAGGCACAGGCAGAC      445                  63
  EXON12 GALNS-R    CAAGCACGTGTGGGTATGAA                          50
  EXON13 GALNS-F    ACATGGTCCCAGTGACTGCT     397                  55
  EXON13 GALNS-R    TGTGCTCTGAGGCACGAG                            61
  EXON14A GALNS-F   TCCCAGCAGCTACTCACTCAG    524                  57
  EXON14A GALNS-R   GGAGGAGGGTCCTGAAATCT                          55
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![Location of mutations in GALNS structure designed in SWISS Protein Data Bank viewer 4.1.0. The active site (C79) is shown in light green spheres.](tacg-11-045Fig1){#f1-tacg-11-045}

![Docking of wild-type GALNS and G6S using PyMOL. The most significant interactions are shown: hydrogen bonds, the O~2~-sulfate group of N-acetylgalactosamine-6-sulfate interacted with p.Gln111 of GALNS, O9 and O7-sulfate of G6S interacted with p.Tyr170, O7 of G6S interacted with p.Arg175 and p.Glu112. Electrostatic interactions with p.Tyr108, p.Cys165, p.Trp520, and p.Pro110.](tacg-11-045Fig2){#f2-tacg-11-045}

###### 

Demographics and characteristics of patients at study entry

  Status                                                                 Statistics                 Value
  ---------------------------------------------------------------------- -------------------------- --------------------------------------------------------
  Number included                                                        n (%)                      15 (46.9) males; 17 (53.1) females
  Age at enrollment                                                      Mean (SD), range (years)   14.5 (10.5) 3--15
  Symptom onset age                                                      Mean (SD)                  2.18 (1.44)
   Symptom onset age distribution                                        \%                         
    Birth--1st year                                                                                 28.1
    1st--3rd year                                                                                   62.5
    3rd -- 7th year                                                                                 9.4
  Age at diagnosis                                                       Range (years)              \<1--29
   Diagnosis age distribution                                            \%                         
    Birth--1st year                                                                                 3.13
    1st--3rd year                                                                                   40.6
    3rd--5th year                                                                                   31.3
    5th -- 12th year                                                                                18.8
    20th--29th year                                                                                 3
  Most common initial symptoms                                           \%                         Pectus carinatum (50)
  Abnormal gait (40.6)                                                                              
  Short stature (31.2)                                                                              
  Most common symptoms at study entry                                    \%                         Short stature, pectus carinatum, and genu valgum (100)
  Abnormal gait (96.9)                                                                              
  Deformity of elbows (81.3)                                                                        
  Scoliosis (75)                                                                                    
  Dislocation of wrist (78.3)                                                                       
  Corneal opacity (63)                                                                              
  Dental abnormalities (75)                                                                         
  Dislocation of hip (56.3)                                                                         
  Hyperlordosis (53.1)                                                                              
  Hearing loss (46.9)                                                                               
  Knee osteoarthritis (40.6)                                                                        
  Cardiac involvement (34.4)                                                                        
  Hip osteoarthrosis (28.1)                                                                         
  Dislocation of the cervical spine (21.9)                                                          
  Cervical spinal cord compression (18.8)                                                           
  Respiratory impairment (15.6)                                                                     
  Surgery (number of patients)                                           n (%)                      19 (59.2)
   Most frequent surgery                                                 \%                         Cervical spine fixation (11.1)
  Osteotomies (14.8)                                                                                
  Myringocentesis (11.1)                                                                            
  Adenectomy (11.1)                                                                                 
  Tonsillectomy (11.1)                                                                              
  Phenotype[a](#tfn1-tacg-11-045){ref-type="table-fn"}                   n (%)                      
   Severe                                                                                           31 (96.88)
   Attenuated                                                                                       1 (3.12)
  Height of male patients[b](#tfn2-tacg-11-045){ref-type="table-fn"}     \%                         
   P3--P10                                                                                          30.7
   P10--P25                                                                                         53.8
   P75                                                                                              15.4
  Height of female patients[b](#tfn2-tacg-11-045){ref-type="table-fn"}   \%                         
   P3--P10                                                                                          14.3
   P25--P50                                                                                         57.1
   P50--P75                                                                                         14.3
   P75--P90                                                                                         7.14
   P90--P97                                                                                         7.14

**Notes:**

Phenotypic severity based on height;[@b13-tacg-11-045]

compared to the reference growth charts developed by Montaño et al.[@b13-tacg-11-045]

###### 

Summary of clinical and biochemical features of the 32 MPS IVA patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Family   Code       Gender   Age of onset (years)   Age at diagnosis (years)   Current age (years)   Height (cm)   Phenotype    Enzymatic activity[a](#tfn3-tacg-11-045){ref-type="table-fn"} (nmol/mg prot/h)   Nucleotide change   Protein change
  -------- ---------- -------- ---------------------- -------------------------- --------------------- ------------- ------------ -------------------------------------------------------------------------------- ------------------- ----------------
  1        MPS IVA\   F        3                      4.0                        7                     92.5          Severe       3.9                                                                              c.1156C\>T\         p.R386C\
           001                                                                                                                                                                                                     c.1156C\>T          p.R386C

  2        MPS IVA\   F        3                      3.0                        26                    130           Attenuated   0.00                                                                             c.491A\>C\          p.N164T\
           002                                                                                                                                                                                                     c.860C\>T           p.S287L

  3        MPS IVA\   M        0.5                    3.0                        9                     97            Severe       0.12                                                                             c.485C\>T\          p.S162F\
           003                                                                                                                                                                                                     c.901G\>T           p.G301C

  4        MPS IVA\   F        2                      3.0                        9                     83            Severe       0.01                                                                             c.485C\>T\          p.S162F\
           004                                                                                                                                                                                                     c.1156C\>T          p.R386C

  5        MPS IVA\   M        7                      9.0                        11                    92            Severe       0.00                                                                             c.860C\>T\          p.S287L\
           005                                                                                                                                                                                                     c.901G\>T           p.G301C

  6        MPS IVA\   F        3                      9.0                        11                    93            Severe       0.00                                                                             c.901G\>T\          p.G301C\
           006                                                                                                                                                                                                     c.1156C\>T          p.R386C

  6        MPS IVA\   M        2                      2.0                        2                     81            Severe       0.00                                                                             c.901G\>T\          p.G301C\
           007                                                                                                                                                                                                     c.1156C\>T          p.R386C

  7        MPS IVA\   F        2                      6.0                        6                     93            Severe       0.06                                                                             c.239C\>T\          p.S80L\
           008                                                                                                                                                                                                     c.239C\>T           p.S80L

  8        MPS IVA\   M        2.5                    3.0                        15                    136           Severe       0.00                                                                             c.485C\>T\          p.S162F\
           009                                                                                                                                                                                                     NF                  NF

  8        MPS IVA\   M        0.5                    0.5                        12                    124           Severe       0.00                                                                             c.485C\>T\          p.S162F\
           010                                                                                                                                                                                                     NF                  NF

  9        MPS IVA\   F        2                      4.0                        10                    93            Severe       3.6                                                                              c.491A\>C\          p.N164T\
           011                                                                                                                                                                                                     c.491A\>C           p.N164T

  10       MPS IVA\   M        0.25                   12.0                       12                    100           Severe       0.02                                                                             c.485C\>T\          p.S162F\
           012                                                                                                                                                                                                     c.485C\>T           p.S162F

  11       MPS IVA\   F        0.5                    29.0                       34                    95            Severe       0.00                                                                             c.901G\>T\          p.G301C\
           013                                                                                                                                                                                                     c.901G\>T           p.G301C

  12       MPS IVA\   M        5                      7.0                        21                    95            Severe       0.07                                                                             c.485C\>T\          p.S162F\
           014                                                                                                                                                                                                     c.901G\>T           p.G301C

  13       MPS IVA\   M        1.5                    3.0                        5                     86            Severe       0.02                                                                             c.901G\>T\          p.G301C\
           015                                                                                                                                                                                                     c.1156C\>T          p.R386C

  14       MPS IVA\   F        0.5                    5.0                        5                     97            Severe       0.04                                                                             c.901G\>T\          p.G301C\
           016                                                                                                                                                                                                     c.901G\>T           p.G301C

  15       MPS IVA\   F        4                      7.0                        38                    98            Severe       0.21                                                                             c.901G\>T\          p.G301C\
           017                                                                                                                                                                                                     c.901G\>T           p.G301C

  16       MPS IVA\   F        1                      4.0                        4                     97            Severe       0.0                                                                              c.901G\>T\          p.G301C\
           018                                                                                                                                                                                                     c.901G\>T           p.G301C

  17       MPS IVA\   M        2                      2.0                        24                    104           Severe       0.02                                                                             c.280C\>T\          p.R94C\
           019                                                                                                                                                                                                     c.974G\>A           p.W325X

  18       MPS IVA\   F        2                      2.0                        5                     89            Severe       0.04                                                                             c.901G\>T\          p.G301C\
           020                                                                                                                                                                                                     c.901G\>T           p.G301C

  19       MPS IVA\   F        3                      5.0                        23                    93            Severe       0.13                                                                             c.901G\>T\          p.G301C\
           021                                                                                                                                                                                                     c.901G\>T           p.G301C

  20       MPS IVA\   F        3                      4.0                        6                     99.5          Severe       0.02                                                                             c\. 319 G\>T\       p\. A107S\
           022                                                                                                                                                                                                     c.901G\>T           p.G301C

  21       MPS IVA\   M        0.4                    5.0                        34                    102           Severe       0.19                                                                             c.901G\>T\          p.G301C\
           023                                                                                                                                                                                                     c.901G\>T           p.G301C

  22       MPS IVA\   F        3                      4.0                        8                     96.5          Severe       0.01                                                                             c.901G\>T\          p.G301C\
           024                                                                                                                                                                                                     c.901G\>T           p.G301C

  23       MPS IVA\   M        1                      1.0                        27                    102           Severe       0.20                                                                             c.901G\>T\          p.G301C\
           025                                                                                                                                                                                                     c.901G\>T           p.G301C

  24       MPS IVA\   F        3                      20.0                       20                    80            Severe       0.00                                                                             c.1156C\>T\         p.R386C\
           026                                                                                                                                                                                                     c.1156C\>T          p.R386C

  25       MPS IVA\   M        2                      3.0                        10                    92            Severe       0.01                                                                             c.485C\>T\          p.S162F\
           027                                                                                                                                                                                                     c.853_855delTTC     p.F285del

  26       MPS IVA\   M        3                      4.0                        16                    93            Severe       0.00                                                                             c.1156C\>T\         p.R386C\
           028                                                                                                                                                                                                     c.1156C\>T          p.R386C

  27       MPS IVA\   F        3                      3.0                        3                     84            Severe       0.06                                                                             c.425A\>T\          p.H142L\
           029                                                                                                                                                                                                     c.901G\>T           p.G301C

  28       MPS IVA\   F        1.5                    2.0                        12                    98.5          Severe       0.03                                                                             c.901G\>T\          p.G301C\
           030                                                                                                                                                                                                     c.901G\>T           p.G301C

  19       MPS IVA\   M        0.7                    2.0                        4                     88.8          Severe       0.00                                                                             c.901G\>T\          p.G301C\
           031                                                                                                                                                                                                     c.901G\>T           p.G301C

  30       MPS IVA\   M        2                      4.0                        35                    107           Severe       0.00                                                                             c.901G\>T\          p.G301C\
           032                                                                                                                                                                                                     c.901G\>T           p.G301C
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Range controls (N = 24): 2.61--15.35.

**Abbreviations:** MPS IVA, mucopolysaccharidosis IVA; NF, not found; M, male; F, female.

###### 

Mutations classification in the gene *GALNS*

  Nucleotide change   Effect on amino acid   Exon   Mutation Classification   New/Reported   Mutation category   Degree of amino acid conservation   Defined phenotype   Detected alleles (n)   Population                       References
  ------------------- ---------------------- ------ ------------------------- -------------- ------------------- ----------------------------------- ------------------- ---------------------- -------------------------------- -----------------------------------------------------------------
  c.239C\>T           p.S80L                 2      Missense                  Reported       Active site         Semi-conserved                      Severe              2                      Br                               Tomatsu et al[@b26-tacg-11-045]
  c.280C\>T           p.R94C                 3      Missense                  Reported       Buried              Semi-conserved                      Severe              1                      Cc, Ca, Br                       Ogawa et al[@b27-tacg-11-045]
  c.319 G\>T          p.A107S                4      Missense                  New            Buried              GALNS-specific                      Severe              1                      Co                               Tapiero et al \[present study\]
  c.425A\>T           p.H142L                5      Missense                  Reported       Active site         Semi-conserved                      Severe              1                      It                               Caciotti et al[@b19-tacg-11-045]
  c.485C\>T           p.S162F                5      Missense                  Reported       Buried              Non-conserved                       Severe              8                      Co                               Kato et al[@b5-tacg-11-045]
  c.491A\>C           p.N164T                5      Missense                  Reported       Buried              GALNS-specific                      Indeterminate       3                      Br                               Tomatsu et al[@b28-tacg-11-045]
  c.853_855delTTC     p.F285del              8      Deletion                  Reported       Buried              GALNS-specific                      Severe              1                      It, Am                           Tomatsu et al[@b29-tacg-11-045]
  c.860C\>T           p.S287L                8      Missense                  Reported       Buried              Semi-conserved                      Severe              2                      Po, Am, Au                       Bunge et al[@b30-tacg-11-045], Tomatsu et al[@b29-tacg-11-045]
  c.901G\>T           p.G301C                9      Missense                  Reported       Buried              Non-conserved                       Severe              32                     Co, Mo, Pt, Bt, Sp               Kato et al[@b5-tacg-11-045], Bunge et al[@b30-tacg-11-045]
  c.974 G\>A          p.W325X                9      Nonsense                  Reported       Buried              Non-conserved                       Severe              1                      Ch                               Wang et al[@b25-tacg-11-045]
  c.1156C\>T          p.R386C                11     Missense                  Reported       Buried              Non-conserved                       Severe              10                     Bt, Jp, It, Mx, Po, Ge, Sp, Tu   Fukuda et al[@b31-tacg-11-045], Tomatsu et al[@b26-tacg-11-045]

**Abbreviations:** Am, American; Au, Austrian; Br, Brazilian; Bt, British; Ca, Canadian; Cc, Caucasian; Ch, Chinese, Co, Colombian; Ge, German; It, Italian; Jp, Japanese; Mo, Moroccan; Mx, Mexican; Po, Polish; Pt, Portuguese; Sp, Spanish; Tu, Turkish.

###### 

Calculated RMSD and ASA for each model of mutant GALNS

  Mutation          Defined phenotype   Energy minimization (kJ/mol)   G6S binding affinity (kcal/mol)   RMSD (Å) C-alpha   ASA (× 10^3^ Å^2^)
  ----------------- ------------------- ------------------------------ --------------------------------- ------------------ --------------------
  Wild-type GALNS                       −28,700.721                    −5.9                                                 18.320
  p.S80L            Severe              −28,211.699                    −5.3                              0.222              18.318
  p.R94C            Severe              −28,379.109                    −5.9                              0.075              18.367
  p\. A107S         Severe              −28,719.574                    −5.2                              0.020              18.321
  p.H142L           Severe              −28,649.404                    −5.1                              0.068              18.329
  p.S162F           Severe              −28,459.688                    −5.1                              0.122              18.317
  p.N164T           Indeterminate       −28,480.713                    −5.2                              0.065              18.321
  p.F285del         Severe              −27,028.111                    −5.9                              6.906              18.335
  p.S287L           Severe              −28,352.705                    −5.1                              0.129              18.318
  p.G301C           Severe              −28,660.238                    −5.1                              0.161              18.319
  p.W325X           Severe              −16,490.084                    −5.0                              4.062              12.773
  p.R386C           Severe              −28,407.244                    −5.1                              0.011              18.370

**Abbreviations:** ASA, accessible surface area; RMSD, root mean square deviation.
